Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver Failure

对乙酰氨基酚引起的急性肝衰竭后肝脏再生的机制

• 批准号: 9040935
• 负责人: Udayan Apte
• 金额: $ 32.84万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2018-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9040935
• 关键词: Acetaminophen; Acetylcysteine; Acute Liver Failure; Analgesic and Antipyretic; Animal Model; Animals; Applications Grants; Biological Markers; Cells; Cessation of life; Chemotactic Factors; Clinical Management; Data; Developed Countries; Developing Countries; Development; Gene Targeting; Glutathione; Glycogen Synthase Kinases; Grant; Health; Hour; Immunosuppressive Agents; Injury to Liver; Leukocytes; Life; Liver Regeneration; Measures; Mus; Natural regeneration; Organ Donor; Outcome; Overdose; Pathway interactions; Patient-Focused Outcomes; Patients; Play; Proteins; Public Health; Reporting; Research; Role; Sampling; Secondary to; Serum; Signal Pathway; Signal Transduction; Testing; Therapeutic; Transplantation; Treatment outcome; Work; acetaminophen overdose; acute liver injury; base; beta catenin; cost; liver cell proliferation; liver transplantation; new therapeutic target; novel; novel marker; novel therapeutics; potential biomarker; predictive modeling; regenerative therapy; therapeutic target

DESCRIPTION (provided by applicant): Overdose of acetaminophen (APAP), the popular analgesic and antipyretic agent, is the most common cause of acute liver failure (ALF) in the developing countries. Treatment options for APAP-induced ALF are extremely limited. Most ALF patients are treated with N-acetyl cystein, a precursor of glutathione, which works only if delivered within hours after APAP overdose. The only other therapy is liver transplantation, which is complicated by scarcity of donor organs, life long immunosuppressant use and exorbitant cost. There is a critical need to develop novel therapies for APAP-induced ALF. Recent studies in animal models and patients have demonstrated that timely stimulation of innate liver regeneration is associated with better outcomes including transplant free survival in APAP-induced ALF. These studies indicate that without proper liver regeneration APAP-induced acute liver injury can develop into ALF and result in death. Whereas these reports have underscored the therapeutic potential of liver regeneration following APAP-induced ALF, the mechanisms of liver regeneration after APAP overdose are not completely known. Our preliminary studies indicate that canonical Wnt signaling culminating in ß-catenin activation plays a critical role in liver regeneration after APAP- induced ALF and could be used for therapeutic targeting. The studies in the first specific aim will determine the role of each component of canonical Wnt pathway including ß-catenin, GSK3ß, disheveled, Lrp5 and Wnt4 in liver regeneration after ALF. Another significant problem in developing regenerative therapies for ALF is the lack of reliable and easy to use biomarkers of liver regeneration. Currently, there are no reliable biomarkers that can be easily measured in serum of ALF patients, which can reveal the status of innate liver regeneration in ALF patients. Predictive models that factor in biomarkers of regeneration will allow clinicians to track status of patient's innate liver regeneration and aid in decisions on listing for transplantation. Our preliminary data indicate tha serum levels of leukocyte derived chemotaxin-2 (Lect2) could be used as a reliable biomarker of liver regeneration following acute liver failure. These studies will not only determine the role of Lect2 as a biomarker of regeneration in ALF but also determine role of Lect2 in stimulation of hepatocyte proliferation providing an additional therapeutic target. Overall, the studies in this grant proposal will determine the mechanisms of liver regeneration and identify novel biomarkers of liver regeneration specific to APAP-induced ALF. Successful completion of these studies will have substantial impact on clinical management of APAP-induced ALF patients.

描述（由申请人提供）：对乙酰氨基酚（APAP）是一种常用的镇痛解热剂，过量服用是发展中国家急性肝衰竭（ALF）的最常见原因。APAP 引起的 ALF 的治疗选择极为有限。 ALF 患者接受 N-乙酰半胱氨酸（谷胱甘肽的前体）治疗，只有在 APAP 过量后数小时内使用才有效。唯一的其他疗法是肝移植。由于供体器官稀缺、终生使用免疫抑制剂和高昂的费用，迫切需要开发针对 APAP 诱导的 ALF 的新疗法。最近对动物模型和患者的研究表明，及时刺激先天性肝脏再生是相关的。这些研究表明，如果没有适当的肝脏再生，APAP 诱导的急性肝损伤可能发展为 ALF 并导致死亡，尽管这些报告强调了肝再生的治疗潜力。 APAP 诱导的 ALF，APAP 过量后肝再生的机制尚不完全清楚，我们的初步研究表明，典型的 Wnt 信号传导最终导致 β-连环蛋白激活，在 APAP 诱导的 ALF 后的肝再生中发挥着关键作用，可用于治疗。第一个具体目标的研究将确定经典 Wnt 通路的每个组件（包括 ß-catenin、GSK3ß、disheveled、Lrp5 和 Wnt4）在肝再生中的作用。继ALF之后，开发ALF再生疗法的另一个重要问题是缺乏可靠且易于使用的肝再生生物标志物，目前尚无可靠的生物标志物可以在ALF患者的血清中轻松测量，从而揭示ALF的状态。 ALF 患者的先天性肝再生。考虑再生生物标志物的预测模型将能够跟踪患者先天性肝再生的状态，并有助于决定是否进行移植。我们的初步数据表明，白细胞的血清水平。 chemotaxin-2 (Lect2) 可用作急性肝衰竭后肝再生的可靠生物标志物。这些研究不仅将确定 Lect2 作为 ALF 再生生物标志物的作用，还将确定 Lect2 在刺激肝细胞增殖中的作用。总体而言，本拨款提案中的研究将确定肝脏再生的机制，并确定针对 APAP 诱导的 ALF 的新型肝脏再生生物标志物，这些研究的成功完成将对临床治疗产生重大影响。 APAP 诱发的 ALF 患者。